Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

US 11752197

Macrophage stimulating 1 receptor (MST1R) variants and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11752214

Protein-antiviral compound conjugates

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11730793

Sustained release formulations using non-aqueous emulsions

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11730150

Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrop

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11732025

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11732024

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11732030

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11730794

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11725034

IL2 agonists and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11713461

Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11713922

Target residual moisture content for lyophilized drug product

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11708415

Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11708416

Methods of treating severe insulin resistance by interfering with glucagon receptor signal

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11707506

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11708407

Antigen binding molecule formats

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11701427

Diels-alder conjugation methods

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11696572

Non-human animals comprising a humanized ASGR1 locus

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11692032

Anti-LAG3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11684050

Non-human animals having a humanized programmed cell death 1 gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11673930

IL10 agonists and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11673967

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11674177

Kelch domain containing 7B (KLHDC7B) variants and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11674968

Methods for identifying free thiols in proteins

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11667701

Anti-PfRH5 antibodies and antigen-binding fragments thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)